Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Bevacizumab in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	GOG-0227C NCT00025233

Trial Description

Purpose:

Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Must have received one or two previous chemotherapy regimens for cancer of the cervix
• Measurable disease
• No CNS disease
• No previous bevacizumab
• At least 3 weeks since biological therapy for cancer of the cervix
• At least 1 week since hormone therapy for cancer of the cervix
• At least 1 month since surgery
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive a 30- to 90-minute infusion of bevacizumab every 3 weeks for as long as benefit is shown. Patients will be evaluated every 3 months for 2 years and every 6 months for 3 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Gynecologic Oncology Group

Bradley Monk, MD, Protocol chair		Ph: 714-456-7974 Email: bjmonk@uci.edu

Registry Information
Official Title		A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865 IND #7921) In the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)
Trial Start Date		2002-04-29
Trial Completion Date		2009-07-19
Registered in ClinicalTrials.gov		NCT00025233
Date Submitted to PDQ		2001-07-30
Information Last Verified		2006-10-26
NCI Grant/Contract Number		CA27469

Back to Top